Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 100,479,976
  • Shares Outstanding, K 2,532,896
  • Annual Sales, $ 22,090 M
  • Annual Income, $ 2,155 M
  • 60-Month Beta 0.47
  • Price/Sales 4.58
  • Price/Cash Flow 10.73
  • Price/Book 8.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.37
  • Number of Estimates 3
  • High Estimate 0.40
  • Low Estimate 0.34
  • Prior Year 0.69
  • Growth Rate Est. (year over year) -46.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.12 +7.45%
on 05/31/19
40.01 -0.32%
on 06/13/19
+2.10 (+5.56%)
since 05/17/19
3-Month
36.83 +8.27%
on 04/30/19
43.29 -7.89%
on 03/21/19
-2.63 (-6.19%)
since 03/15/19
52-Week
34.38 +16.00%
on 06/28/18
43.29 -7.89%
on 03/21/19
+3.47 (+9.53%)
since 06/15/18

Most Recent Stories

More News
AstraZeneca Gives Detailed Data From Calquence Leukemia Study

AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.

AZN : 39.92 (+0.63%)
GILD : 67.14 (+1.18%)
RHHBY : 34.4900 (-0.17%)
BIIB : 232.72 (+2.22%)
CALQUENCE(R) (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia

AstraZeneca today announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association (EHA) Annual Congress in Amsterdam, showing CALQUENCE(R)...

AZN : 39.92 (+0.63%)
Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod

Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.

AZN : 39.92 (+0.63%)
NVO : 51.30 (+0.67%)
MRK : 82.97 (+0.23%)
JNJ : 139.50 (-0.42%)
LLY : 112.48 (+0.66%)
RHHBY : 34.4900 (-0.17%)
SNY : 42.56 (+0.21%)
LOKELMA(TM) Demonstrated Efficacy in Treating Hyperkalemia in Patients with End-Stage Renal Disease on Hemodialysis

AstraZeneca today presented positive results from the Phase IIIb DIALIZE trial which investigated the efficacy and safety of LOKELMA (sodium zirconium cyclosilicate) for the treatment of...

AZN : 39.92 (+0.63%)
Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock

Here are five reasons why investors may consider betting on Merck (MRK) stock

AZN : 39.92 (+0.63%)
MRK : 82.97 (+0.23%)
INCY : 81.97 (+5.48%)
AMGN : 177.85 (+1.01%)
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca

The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca

MSFT : 133.07 (+0.47%)
CRUS : 40.46 (+1.51%)
AZN : 39.92 (+0.63%)
MRK : 82.97 (+0.23%)
LLY : 112.48 (+0.66%)
INFY : 10.60 (-0.09%)
RHHBY : 34.4900 (-0.17%)
SIMO : 40.00 (-0.47%)
BMY : 48.26 (+1.47%)
FARXIGA Study Showed Reduced Progression of Kidney Disease or Renal Death in Patients with Type 2 Diabetes

A pre-specified exploratory analysis of renal data from the Phase III DECLARE-TIMI 58 trial, the broadest cardiovascular outcomes trial of a sodium-glucose co-transporter 2 (SGLT2) inhibitor,...

AZN : 39.92 (+0.63%)
AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study

AstraZeneca's (AZN) lymphoma drug, Calquence, meets the primary endpoint and a key secondary one in a phase III study for the first-line treatment of chronic lymphocytic leukaemia.

AZN : 39.92 (+0.63%)
MRK : 82.97 (+0.23%)
ABBV : 78.88 (+0.24%)
RHHBY : 34.4900 (-0.17%)
Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache

Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.

AZN : 39.92 (+0.63%)
MRK : 82.97 (+0.23%)
JNJ : 139.50 (-0.42%)
LLY : 112.48 (+0.66%)
RHHBY : 34.4900 (-0.17%)
SNY : 42.56 (+0.21%)
BMY : 48.26 (+1.47%)
Was ASCO Quieter for Big Drug/Biotech Stocks This Year?

The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.

AZN : 39.92 (+0.63%)
MRK : 82.97 (+0.23%)
NVS : 89.78 (+0.29%)
RHHBY : 34.4900 (-0.17%)
AMGN : 177.85 (+1.01%)
SNY : 42.56 (+0.21%)
BMY : 48.26 (+1.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade AZN with:

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Key Turning Points

2nd Resistance Point 40.09
1st Resistance Point 39.88
Last Price 39.92
1st Support Level 39.54
2nd Support Level 39.41

See More

52-Week High 43.29
Last Price 39.92
Fibonacci 61.8% 39.89
Fibonacci 50% 38.84
Fibonacci 38.2% 37.79
52-Week Low 34.38

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar